OrbiMed’s Regeneron Pharmaceuticals REGN Stock Holding History

OrbiMed’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.4M	Buy	+14,700	New	+$11.3M	0.23%	77
2024 Q4	–	Sell	-45,200	Closed	-$47.5M	–	134
2024 Q3	$47.5M	Buy	45,200 +22,400	+98%	+$24.9M	0.86%	34
2024 Q2	$24M	Hold	22,800	–	–	0.47%	54
2024 Q1	$21.9M	Buy	22,800 +9,300	+69%	+$8.84M	0.4%	60
2023 Q4	$11.9M	Hold	13,500	–	–	0.24%	74
2023 Q3	$11.1M	Hold	13,500	–	–	0.24%	81
2023 Q2	$9.7M	Sell	13,500 -10,500	-44%	-$8.1M	0.18%	87
2023 Q1	$19.7M	Buy	+24,000	New	+$18.1M	0.39%	67
2022 Q3	–	Sell	-22,200	Closed	-$13.1K	–	143
2022 Q2	$13.1K	Buy	+22,200	New	+$14.4M	0.24%	77
2021 Q4	–	Sell	-13,560	Closed	-$8.21M	–	175
2021 Q3	$8.21M	Buy	+13,560	New	+$8.42M	0.09%	138
2020 Q3	–	Sell	-30,900	Closed	-$19.3M	–	157
2020 Q2	$19.3M	Buy	30,900 +13,700	+80%	+$7.78M	0.27%	79
2020 Q1	$8.4M	Sell	17,200 -192,100	-92%	-$79.2M	0.14%	92
2019 Q4	$78.6M	Sell	209,300 -18,800	-8%	-$6.33M	1.12%	32
2019 Q3	$63.3M	Buy	228,100 +12,300	+6%	+$3.64M	1.2%	29
2019 Q2	$67.5M	Buy	215,800 +1,000	+0.5%	+$333K	1.05%	32
2019 Q1	$88.2M	Sell	214,800 -7,300	-3%	-$3.01M	1.37%	21
2018 Q4	$83M	Sell	222,100 -172,300	-44%	-$63.1M	1.53%	17
2018 Q3	$159M	Buy	394,400 +21,900	+6%	+$8.33M	1.92%	14
2018 Q2	$129M	Sell	372,500 -590,400	-61%	-$185M	1.53%	16
2018 Q1	$332M	Buy	962,900 +108,300	+13%	+$37.7M	4.11%	2
2017 Q4	$321M	Buy	854,600 +281,830	+49%	+$114M	4.06%	3
2017 Q3	$256M	Buy	572,770 +106,000	+23%	+$50.4M	2.45%	9
2017 Q2	$229M	Buy	466,770 +88,600	+23%	+$38.8M	2.4%	9
2017 Q1	$147M	Buy	378,170 +22,870	+6%	+$8.48M	1.66%	18
2016 Q4	$130M	Hold	355,300	–	–	1.66%	20
2016 Q3	$143M	Sell	355,300 -154,600	-30%	-$62M	1.63%	21
2016 Q2	$178M	Sell	509,900 -23,100	-4%	-$8.9M	1.86%	16
2016 Q1	$192M	Buy	533,000 +50,000	+10%	+$20.6M	2.02%	14
2015 Q4	$262M	Sell	483,000 -4,700	-1%	-$2.55M	2.37%	13
2015 Q3	$227M	Buy	487,700 +25,900	+6%	+$13.9M	2.29%	12
2015 Q2	$236M	Buy	461,800 +40,000	+9%	+$19.5M	1.97%	20
2015 Q1	$190M	Buy	421,800 +31,600	+8%	+$13.4M	1.63%	25
2014 Q4	$160M	Buy	390,200 +20,600	+6%	+$8.1M	1.53%	27
2014 Q3	$133M	Buy	369,600 +43,000	+13%	+$14.4M	1.39%	30
2014 Q2	$92.3M	Sell	326,600 -212,400	-39%	-$63M	1.08%	34
2014 Q1	$162M	Sell	539,000 -199,800	-27%	-$61.6M	1.99%	19
2013 Q4	$203M	Buy	738,800 +225,700	+44%	+$64.9M	2.99%	8
2013 Q3	$161M	Buy	513,100 +162,000	+46%	+$42.6M	2.86%	9
2013 Q2	$79M	Buy	+351,100	New	+$81.8M	1.67%	23

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

OrbiMed's REGN Position: Q1 2026 in Review

OrbiMed opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 14,700 shares worth $11.4M. The stake represents 0.23% of the portfolio and ranks #77 among its holdings. This is a return to the name: OrbiMed previously reported a position in REGN as recently as Q3 2024.

OrbiMed first reported a position in REGN in Q2 2013 and has held it in 39 quarters since. The position peaked at $332M in Q1 2018. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

OrbiMed held 14,700 shares of Regeneron Pharmaceuticals worth $11.4M as of Q1 2026.
Regeneron Pharmaceuticals was a new OrbiMed position in Q1 2026.
Regeneron Pharmaceuticals made up 0.23% of OrbiMed's portfolio in Q1 2026, its #77 holding.
OrbiMed first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 39 quarters since.
OrbiMed's Regeneron Pharmaceuticals position peaked at $332M in Q1 2018.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.